The Pharma Data

DECEMBER 3, 2020

Strong Th1 cell-mediated immune responses were also observed for the vaccine candidates with either adjuvant. We are encouraged by the high level of neutralizing antibodies in combination with the strong Th1 response which we believe could play an important role in controlling infection. About Clover Biopharmaceuticals.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Drug Target Review

APRIL 3, 2024

Could you share an example of a specific project or research that you have worked on and the impact it has had in your field? We continue our research to gain further insights into the underlying biology of GDF-15 and its role in cancer pathogenesis and treatment resistance. in North America) in late 2017.

Science 105

Science Clinical Development Treatment DNA 105

The Pharma Data

JANUARY 31, 2021

Adjuvanted S-Trimer COVID-19 vaccine candidates demonstrated favorable safety and tolerability profiles and strong neutralizing immune responses in a phase 1 trial. Dynavax is also advancing CpG 1018 as an advanced vaccine adjuvant through research collaborations and partnerships. CHENGDU, China , Feb.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

JANUARY 31, 2021

Clover’s S-Trimer antigen adjuvanted with CpG 1018 plus alum demonstrated low reactogenicity while providing high levels of neutralizing antibodies and a strong Th1-biased cell-mediated immune response. Dynavax developed CpG 1018 to provide an increased vaccine immune response, which has been demonstrated in HEPLISAV-B.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

DECEMBER 15, 2020

However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The human monoclonal antibody targets specific immune plasma cells. New Immune System Cell.

Disease 52

Disease Clinical Trials Small Molecule Trials 52

Drug Target Review

DECEMBER 5, 2024

Among them, adeno-associated viruses (AAVs) stand out due to their small size, high efficiency in gene delivery, low immunogenicity, and potential for customisable tissue targeting, making them the leading tool in gene expression research.

Therapies 52

Therapies Virus DNA Compliance 52

The Pharma Data

NOVEMBER 10, 2020

This potentially ground-breaking approach for immunotherapies originated in my laboratory and was subsequently reported by other researchers in the field.”. Recently, we also successfully demonstrated that nasally administered Foralumab is not only well-tolerated, but also produced desirable immunological responses. da Cunha, A.

Clinical Trials 40

Clinical Trials Science Disease Trials 40

The Pharma Data

NOVEMBER 9, 2020

executive vice president of Research and Development at Amgen. Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 52

Trials Production Clinical Trials Government 52

Broad Institute

MAY 21, 2025

The Merkin Prize recognizes novel technologies that have improved human health and is administered by the Broad Institute, one of the worlds leading biomedical research institutes. He showed that these synthetic CAR T cells could launch an immune response when they encountered the corresponding tumor protein, called CD19.

Therapies 119

Therapies FDA Approval Engineering Immune Response 119

The Pharma Data

DECEMBER 21, 2020

executive vice president of Research and Development at Amgen. Specifically, tezepelumab targets and blocks TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma.

Trials 40

Trials Production Clinical Trials Therapies 40

BioPharma Drive: Drug Pricing

JUNE 27, 2025

Dive Insight: Since the FDA’s approval of Novartis’ Kymriah for leukemia in 2017, six more CAR-T therapies have reached market. These medicines are made from a patient’s own immune cells, extracted from the body and engineered in a lab to hunt down specific proteins found on the surface of malignant clones.

Therapies 182

Therapies FDA Treatment Licensing 182

Broad Institute

OCTOBER 11, 2023

Manguso, who’d recently graduated from college and was conducting research at the University of Copenhagen as a Fulbright scholar, moved back to the Boston area to be with his mother as she underwent treatment. They are used to treat cancers including melanoma and non-small cell lung cancer, but work only for a small fraction of patients.

Research 137

Research Immune Response Clinical Trials Therapies 137

Codon

JUNE 5, 2025

The core of the CRISPR immune response is a guide RNA (gRNA) that binds to a CRISPR-associated (Cas) protein. Researchers have since discovered variants of the protein with additional useful qualities. Researchers have also discovered a slew of small Cas9s — some less than half the size of the S.

DNA 78

DNA RNA Clinical Trials Engineering 78

Drug Target Review

OCTOBER 26, 2023

Alipogene tiparvovec and voretigene neparvovec-rzyl, two recombinant AAV-based gene therapy products, were approved by the European Medicines Agency (EMA) to treat lipoprotein lipase deficiency in 2012 2 and by the US Food and Drug Administration (FDA) to treat inherited retinal dystrophy in 2017, respectively.

Engineering 105

Engineering Virus Therapies Immune Response 105

Drug Target Review

OCTOBER 2, 2024

Early-phase clinical trials have shown the safety and efficacy of using stem cells for cardiac repair, encouraging further research and development. While commonly used, AAVs have limitations, including immune reactions and difficulties with re-dosing due to pre-existing antibodies. 2017 May 31;58(3):435-440. Epub 2017 May 23.

Therapies 98

Therapies Disease RNA Engineering 98

The Pharma Data

APRIL 8, 2022

Now, new research from the Wyss Institute at Harvard University has revealed that this constant pattern of stretching and relaxing does even more – it generates immune responses against invading viruses. a Wyss Technology Development Fellow at the Institute. ” The results are published today in Nature Communications.

Virus 52

Virus Immune Response Disease Clinical Trials 52

PerkinElmer

AUGUST 25, 2019

1 AlphaLISA ® Assay Technology Studies done using human tumor cell lines by PerkinElmer Application Scientist Jeanine Hinterneder have contributed to our understanding of how tumor cells develop the ability to evade the immune response. When that occurs the cancer becomes more severe.

Protein Expression 52

Protein Expression Immune Response Treatment Research 52

PLOS: DNA Science

OCTOBER 12, 2023

Can they deliver healing genes without triggering an overactive immune response? The details are disturbingly reminiscent of the famous case of Jesse Gelsinger , who died from a ferocious immune response to experimental gene therapy in September 1999. An immune response is two-tiered.

Therapies 69

Therapies Immune Response DNA Virus 69

The Pharma Data

SEPTEMBER 10, 2021

Imfinzi (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Since the first approval in May 2017, more than 100,000 patients have been treated with Imfinzi.

Treatment 52

Treatment Immune Response Trials Clinical Trials 52

The Pharma Data

JUNE 18, 2021

Senior Vice President and Head of Vaccine Research & Development, Pfizer. With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.”. Jansen, Ph.D., IMPORTANT SAFETY INFORMATION.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

The Pharma Data

NOVEMBER 1, 2020

This clinical trial will be coordinated by the team at the INTRIALS, a leading, full-service Latin America Clinical Research Organization (CRO), based in Sao Paulo City, Brazil. The clinical data from this trial is expected to available by the end of this year. Brazil has reported almost 5.5M

Clinical Trials 40

Clinical Trials Trials Medical Schools Hospitals 40

The Pharma Data

MARCH 16, 2021

Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. for the treatment of adults with moderate to severe plaque PsO in July 2017 and in July 2020 for adults with active PsA. TREMFYA was approved in the U.S. 4,5 Complete study results were previously published in The Lancet.

Treatment 52

Treatment Disease Pharmacokinetics Therapies 52

The Pharma Data

MARCH 11, 2021

In 2017, Opdivo was granted accelerated approval by the FDA as a single agent for patients with HCC who have been previously treated with sorafenib. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. About Opdivo.

Treatment 52

Treatment Trials Therapies FDA Approval 52

The Pharma Data

OCTOBER 28, 2020

Adults with COVID-19 ARDS As cases of COVID-19 surge in the United States and globally, deaths continue to increase from ARDS in ventilator-dependent patients as a result of an overactive immune response in the lungs to COVID-19. Research and Development payments were US$9.9 In addition, $5.2 TEMCELL ® HS Inj.

Treatment 40

Treatment Trials Disease Production 40

The Pharma Data

APRIL 7, 2023

Imfinzi Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses.

Trials 40

Trials DNA Treatment Therapies 40

The Pharma Data

JULY 23, 2021

Opdivo was first granted this indication in 2017 under the FDA’s accelerated approval program, making it the first immunotherapy agent to be approved for use in this setting. The accelerated approval was based on tumor responses from the Phase 1/2 CheckMate -040 trial. About Opdivo.

Treatment 52

Treatment Trials Therapies Disease 52

Drug Target Review

OCTOBER 4, 2023

The research community pressed on, turning to novel compounds that were substantially more potent than those used in the first generation. Associating immunomodulatory and cytotoxic payloads on the same ADC could also amplify the therapeutic effect of cytotoxic payloads harnessing the power of the immune system to target tumour cells.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. THERAPEUTIC AREAS OF FOCUS.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Drug Target Review

JANUARY 15, 2024

Our innate immune system evolved to clear genetically diverse pathogens and limit host toxicity, raising the possibility that it can produce similar effects in cancer. What aspects prompted this research direction? The preclinical results demonstrated significant immune responses and tumour regression.

Treatment 105

Treatment Immune Response Therapies Clinical Trials 105

Drug Target Review

FEBRUARY 25, 2025

Dr Jonathan Zalevsky, the companys chief research & development officer, has played a pivotal role in driving the development of NKTR-255. With over 20 years of experience in the biopharmaceutical industry, particularly in oncology and immunology, Zalevskys work has helped shape the companys approach to immune-oncology.

Therapies 52

Therapies Immune Response Treatment Clinical Trials 52

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. 2017; 61(3): e01714-16. The primary analysis was based on 5,172 participants who did not have SARS-CoV-2 infection at baseline. Antimicrob Agents Chemother. Yu XQ, et al.

Trials 52

Trials Virus Vaccine Pharmacokinetics 52

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Oncologist Kerry Reynolds (left) and researcher Alexandra-Chloé Villani (right) work together to better understand and treat complications of immunotherapy. Patients can even develop life-threatening organ inflammation after a single dose. How did you go about launching this effort?

Research 131

Research Immune Response Hospitals Therapies 131

Broad Institute

NOVEMBER 6, 2024

By Leah Eisenstadt November 6, 2024 Credit: Ricardo Job-Reese, Broad Communications Despite being one of the rarer complications from immune checkpoint inhibitors, myocarditis is the most deadly. This work provides a biological foundation for testing more targeted therapies for myocarditis due to an immune checkpoint inhibitor.

Immune Response 125

Immune Response Medical Schools Clinical Trials Treatment 125